Perseverance Capital Management
VC Fund
Los Angeles, United States
Perseverance Capital Management is an asset management firm investing in the healthcare sector.It is a long-term investor and believes that it is critical to be a value-added investor by actively working with portfolio company management teams to help build market-leading companies. They are committed to building businesses through deepcollaborative partnerships with world-class scientists, clinicians, outstanding entrepreneurs, and management teams. The investment objective of Perseverance is to not only achieve a long-term capital appreciation for their investors but also to partner, build, operate, and finance companies that have the potential to make a difference in patients' lives.The Los Angeles, California-headquartered firm was founded in 2013.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Perseverance Capital Management invests in
Stages Perseverance Capital Management invests in
Countries Perseverance Capital Management invests in
Round sizes
Round size
- Seed
- $5M–$10M
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 2 (33%)
- Medical Device 2 (33%)
- Blockchain 1 (17%)
Stage
- Seed 2 (33%)
- Series C 2 (33%)
- Series B 1 (17%)
- Series D 1 (17%)
Country
- United States 4 (67%)
- Mexico 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kailera Therapeutics
|
Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. | $600M / Series B / Oct 14, 2025 | |
VelaFi
|
Galactic Holdings offers a series of digital finance products. | $10M / Seed / Apr 17, 2023 | |
MindRhythm
|
MindRhythm is a medical device company focused on applying novel biometrics to stroke and concussion patients to improve diagnosis, triage and management. Their proprietary monitoring devices and communication platform provide novel and real-time visibility to life-threatening situations prehospital and in the operating room, allowing clinicians tointervene earlier and with better precision to prevent brain damage. | $5M / Seed / Aug 24, 2021 | |
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $47M / Series D / Dec 10, 2020 | |
|
CG Oncology
|
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. | $22M / Series C / Mar 18, 2019 | |
NxThera
|
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States. | Series C |
Co-Investors
ORI Capital
2 deals together
Aestus Capital
1 deal together
Animoca Brands
1 deal together
Bain Capital Private Equity
1 deal together
BAI capital
1 deal together
Blue Fog Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Perseverance Capital Management invest in?
Perseverance Capital Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Perseverance Capital Management's check size?
Perseverance Capital Management typically joins rounds of $5M–$10M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Perseverance Capital Management participates in.
When did Perseverance Capital Management last invest?
The most recent investment recorded for Perseverance Capital Management closed in Oct 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
